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Kinetic studyAbstract Nitrogen mustard (mustine) containing an established anticancer moiety (N,N-bis(2-
chloroethyl)amino is the one of the most active and widely used alkylating anticancer agents but
it is too polar to cross the blood–brain barrier. The present study evaluates the utility of the dihy-
dropyridineMpyridinium salt redox system for the speciﬁc delivery and sustained release of bis-(2-
chloroethyl)amine as anticancer moiety to the brain as an initial effort in a search for agents that
may prove effective as CNS antitumor agent. The cytotoxic moiety bis-(2-chloroethyl)amine was
converted into the corresponding 1-methyl-3-[bis-(20-chloroethyl)amino]carbamoyl-1,4 dihydropyr-
idine (CDS-mustard) (4), in three steps. Structures of all the synthesized compounds were charac-
terized by UV, IR and 1H NMR and 13C NMR spectroscopic studies. In vitro chemical
oxidation studies with silver nitrate of CDS-mustard indicated that it can be readily converted into
its corresponding salt (3). In vitro kinetic studies of CDS-mustard showed that its rate of oxidation
followed pseudo-ﬁrst-order kinetics with reasonable half-lives in biological media. The study of
some other physicochemical parameter calculated by online software also indicates that it can be
a potential CNS antitumor agent.
ª 2012 Production and hosting by Elsevier B.V. on behalf of King Saud University.1. Introduction
Primary and secondary metastatic tumors of the CNS repre-
sent a major health problem globally. They are the second
leading cause of cancer death in male adults aged 20–29 and
the ﬁfth leading cause of cancer death in female adults aged
20–39. Male are affected more than females. More than
200,000 people in the United States are estimated to be diag-
nosed with a primary or metastatic brain tumor (Jemal
et al., 2010). Still, where possible, surgery remains the pre-
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performed in conjunction with chemotherapy. But chemother-
apy by antineoplastic agents is a challenge in the treatment of
brain tumor. Many potential useful drugs including those ac-
tive against peripheral tumors such as chlorambucil and mel-
phalan due to their hydrophilicity cannot enter the brain and
are therefore ineffective in treating cerebral neoplasms. The
major obstruction to CNS drug delivery is the blood–brain
barrier, which limits the access of drugs to the brain substance.
The BBB comprises the endothelial lining of the microvessels
in the brain, pericytes and astrocytes, and is the main barrier
to drug transport into the CNS especially for labile hydrophilic
compounds. In fact, it is estimated that only about 2% of po-
tential CNS compounds can penetrate the BBB (Ambrose and
Sheng-He, 2005).
Various attempts have been made to overcome the limited
access of anticancer agent into the brain by synthesizing the
lipophilic analogs of alkylating anticancer agent (Genka
et al., 1993) or by linking the active anticancer moiety to lipo-
philic carrier (Peng et al., 1975; Bartzatt, 2004).
One of the most promising approaches for brain delivery is
the concept of brain-speciﬁc drug delivery system based on a
redox system analogous to the endogenous NADHMNAD+
coenzyme system developed by Bodor et al. (1981). TheScheme 1 Reagents and conditions: (i) Thionyl chloride; (ii) M
chloroethylamine; (iii) methyl iodide, acetone; (iv) sodium bicarbonatedihydropyridineMquaternary salt redox system based chemi-
cal delivery system (CDS) has been investigated extensively
as a method to enhance the selective delivery of drugs to the
brain (Prokai et al., 2000). After entry into the brain, the
CDS moiety is oxidized to a polar pyridinium species that can-
not egress from the brain which then undergoes ester or amide
cleavage to release the active drug and trigonelline.
This redox delivery system was successfully applied for
brain-speciﬁc delivery of various alkylating anticancer agents.
Chlorambucil (chlorambucil–CDH) (Bodor et al., 1989) and 1-
(2-chloroethyl)3-cyclohexyl-1-nitrosourea (CCNU–CDH)
(Raghavan et al., 1987) have been investigated to provide im-
proved brain delivery relative to the parent compounds chlor-
ambucil and CCNU, respectively. This system has also
successfully been utilized to deliver nitrogen mustard group
to the brain with ethyl as spacer group with promising results
(EI-Sherbeny et al., 2003). Clearly there is a great need to de-
velop therapeutic strategies that will provide efﬁcient antican-
cer drug delivery to brain tumors. So it was therefore of
interest to synthesize redox derivative of bis-(2-chloro-
ethyl)amine (normustard) as alkylating anticancer moiety to
the Bodor CDS directly, without any spacer group to evaluate
its efﬁcacy as a CNS anticancer agent by the given synthetic
Scheme 1.ethod A: diethanolamine, thionyl chloride), Method B: bis(2-
, sodium dithionite; (v) Trace amount of moisture, rearrangement.
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All the reagents and solvents used are purchased from the commer-
cial suppliers. Themelting points were determined onVeego-melt-
ing point apparatus and are uncorrected. Proton (1H) nuclear
magnetic resonance (1H NMR) and 13C NMR spectra were ob-
tained using Brucker AC-400 F, 400 MHZ spectrometer and are
reported in parts permillion (ppm), downﬁeld from tetramethylsil-
ane (TMS) as internal standard. Infrared (IR) spectra were ob-
tained with Perkin Elmer 882 Spectrum and RXI, FT-IR model
using a potassium bromide pellets (in cm1). The ultraviolet spec-
tra were recorded on Shimadzu, UV-1800 spectrophotometer.
Reactions were monitored and the homogeneity of the products
was checked by TLC which were prepared with silica gel G and
activated at 110 C for 30 min. The plateswere developed by expo-
sure to iodine vapors. Anhydrous sodium sulfate was utilized as
drying agents. All the solvents were dried and freshly distilled prior
to use according to the standard procedure. A computational
studyof titled compoundswasperformed forpredictionofADME
properties. Polar surface area (TPSA), milogP, number of rotat-
able bonds, molecular volume, number of hydrogen donor and
acceptor atoms and violations of Lipinski’s rule of ﬁve were calcu-
lated using Molinspiration online property calculation toolkit.
2.1. Synthesis of nicotinoyl chloride (1)
The nicotinic acid 3.5 gm (28.6 mmol) and freshly distilled
thionyl chloride (10.0 ml) were reﬂuxed for 6 h on a water
bath. Excess thionyl chloride was distilled on vacuo and the
product coevaporated with chloroform to get needle shape
pale yellow crystal which was used without further puriﬁcation
for the next reaction.
2.2. Synthesis of N,N-bis(2-chloroethyl)carbamoyl pyridine (2)
This can be prepared by two methods:
Method A: The 3.5 gm (28.6 mmol) of nicotinoyl chloride
was added in 50.0 ml of dry toluene. The solution was cooled
in an ice bath and a solution of 5.12 gm (28.6 mmol) of dieth-
anolamine and 2.0 ml of triethylamine was dropped in while
stirring over 10 min and the mixture was reﬂuxed for 6 h and
then stirred overnight. The precipitate formed was ﬁltered
and the residue evaporated to obtain the intermediate diol
which was treated with thionyl chloride and reﬂuxed under a
water bath for 3 h. The excess thionyl chloride was distilled un-
der vacuum to obtain the ﬁnal compound which was recrystal-
lized from isopropanol to obtain yellow oil in 62% yield (3).
Method B: The solution of nicotinoyl chloride (3.5 g,
28.6 mmol) in dry toluene (50 ml) was slowly added (10 min)
to a dry toluene (20 ml) solution (ice-bath cooling) of the free
amine from 5.12 g (28.6 mmol) of bis(2-chloroethyl)amine
hydrochloride in the form of free base which was prepared by
adding 5% NaOH solution and extracting with diethyl ether.
The mixture was heated at reﬂux for 4 h. Removal of solvent
from the ﬁltrate led to compound (2) as yellow oil in 54% yield.
2.2.1. Anal.
Rf = 0.46 (chloroform:methanol, 9:1).
IR (KBr): 3016 cm1(C–H), 1661 cm1 (C‚O), 1226,
1129, 1020 cm1 (C–N) and 760 cm1 (C–Cl).1H NMR (DMSO-d6): d 3.2 (t, 4H, J= 5.7 Hz, –
N(CH2CH2Cl)2), d 3.7 (t, 4H, J= 7.8 Hz, –
N(CH2CH2Cl)2), d 7.4 (t, 1H, J= 2.3 Hz, C5 pyridine pro-
ton), d 8.3 (d, 1H, J= 2.0 Hz, C4 pyridine proton), d 8.7 (d,
1H, J= 1.70 Hz, C6 pyridine proton), d 9.2 ppm (s, 1H, C2
pyridine proton).
13C NMR (DMSO-d6): d (ppm): 167.2 (C‚O), 152 (C-2
pyr), 147.2 (C-6 pyr), 134.0 (C-4 pyr), 129.8 (C-3 pyr),
122.5 (C-5 pyr), 51.4 (C–N), 42.2 (C–Cl).
2.3. Synthesis of 1-methyl-3-[bis(2-
chloroethyl)amino]carbamoyl-pyridinium iodide (3)
To a solution of 1.0 gm (4 mmol) of N,N-bis(2-chloro-
ethyl)carbamoyl pyridine and 30.0 ml of acetone was added
1.136 g (8 mmol) of methyl iodide, and the mixture was re-
ﬂuxed with stirring for 24 h. The yellow hygroscopic residue
that separated was ﬁltered, washed with acetone and dried.
Yield: (65%).
2.3.1. Anal.
Rf = 0.2 (chloroform:methanol, 8:2).
UVmax (H2O): 275 nm.
IR (KBr): 3016 cm1(C–H), 1661 cm1 (C‚O), 1226,
1129, 1020 cm1 (C–N) and 760 cm1 (C–Cl).
1H NMR (DMSO-d6): d 3.2 (t, 4H, J= 7.16 –
N(CH2CH2Cl)2), d 3.6 (t, 4H, J= 6.20, –N(CH2CH2Cl)2),
d 4.6 (s, 3H, –N+CH3) d 8.3 (t, 1H, J= 6.8, C5 pyridine
proton), d 8.6 (d, 1H, J= 9.6, C4 pyridine proton), d 9.3
(d, 1H, J= 5.84, C6 pyridine proton), d 10.2 ppm (s,
1H,C2 pyridine proton).
13C NMR (DMSO-d6): d (ppm): 167.8 (C‚O), 148.4 (C-2
pyr), 148.1 (C-4 pyr), 145.2 (C-6 pyr), 138.0 (C-3 pyr), 128.4
(C-5 pyr), 50.7 (C–N), 46.8 (N+Me), 43.4 (C–Cl).
2.4. Synthesis of 1-methyl-3-[bis(2-
chloroethyl)amino]carbamoyl-1,4-dihydropyridine (4)
To a solution of 0.9 gm (3.4 mmol) of 1-methyl-3-[bis(2-chlo-
roethyl)amino]carbamoyl-1,4-dihydropyridinium iodide,
20.0 ml deaerated water, and 20.0 ml of ethyl acetate were
added 1.7 gm (20.4 mmol) of sodium bicarbonate and
2.38 gm (13.6 mmol) of sodium dithionite. The mixture was
stirred under nitrogen for 1 h in an ice bath. The ethyl acetate
layer was separated, and aqueous layer was re-extracted twice
with 20.0 ml of ethyl acetate. The combined organic layer was
washed with cold deaerated water, dried over anhydrous
Na2SO4, and distilled on vacuo. The yellow colored gummy
residue preserved in desiccators protected from light and air.
Yield: 60%.
2.4.1. Anal.
Rf = 0.55 (chloroform:methanol, 9:1).
UVmax (CH3OH): 320 nm.
IR (KBr): 2961 cm1(C–H), 1638 cm1 (C‚O), 1110,
1210 cm1 (C–N) and 742 cm1 (C–Cl).
Synthesis, physicochemical and kinetic studies of redox derivative of bis(2-chloroethylamine) as alkylating 3831H NMR (DMSO-d6): d 2.8 (s, 3H, –NCH3), d 3.0 (t, 4H,
J= 4.0 Hz, –N(CH2CH2Cl)2), d 3.5 (t, 4H, J= 4.7 Hz, –
N(CH2CH2Cl)2), d 4.1 (br s, 2H, C4 pyridine proton), d
4.7 (t, 1H, J= 4.0 Hz, C5 pyridine proton), d 5.6 (d, 1H,
J= 6.3 Hz, C6 pyridine proton) and d 7.0 ppm (s, 1H, C2
pyridine proton).
13C NMR (DMSO-d6): d (ppm): 172.2 (C‚O), 147.8(C-2
pyr), 134.0 (C-6 pyr), 121.2 (C-3 pyr), 108.0 (C-5 pyr),
31.4 (C-4 pyr), 52.8 (C–N), 43.6 (N-Me), 36.8 (C–Cl).
2.5. Synthesis of N-[2-(2-chloroethylamino)ethoxycarbonyl]
pyridine hydrochloride (5)
N,N-bis(2-chloroethyl)carbamoyl pyridine (2) (5.0 mmol) was
dissolved in 10 ml of water and stirred for 30 min at room tem-
perature. The reaction mixture was basiﬁed by dilute sodium
hydroxide solution to precipitate oil which was soluble in
hydrochloric acid.
IR (KBr): 3429 cm1 (N–H), 1720 cm1 (–OC‚O), 1050–
1230 cm1 (C–N) and 740 cm1 (C–Cl).
1H NMR (DMSO-d6): d 3.7 (m, 4H, –CH2NHCH2–), d 4.2
(t, 2H, J= 7.2 Hz, –CH2CH2Cl–), d 4.7 (t, 2H, J= 7.4 Hz,
–OCH2CH2–), d 7.4 (t, 1H, J= 2.8 Hz, C5 pyridine pro-
ton), d 8.3 (d, 1H, J= 2.2 Hz, C4 pyridine proton), d 8.7
(d, 1H, J= 2.4 Hz, C6 pyridine proton), d 9.2 ppm (s,
1H, C2 pyridine proton).
2.6. NBP alkylation assay
The alkylation activity of prepared Q-CDS-mustard (3) was
determined as per the given literature procedure (Pen et al.,
2002). Thus a solution of Q-CDS-mustard or N-di(2-chloro-
ethyl amine)[–NH(CH2CH2Cl)2] in different concentrations as
indicated in Table 1 in acetone (1 ml), distilled water (1 ml)
and acetate buffer (1 ml, 0.25 M, pH 6.0) were incubated at
100 C for 20 min with a solution of 4-(4-nitro-benzyl) pyridine
(NBP) (5% w/v) in acetone (0.4 ml) and cooled to 25 C. After
the addition of acetone (2 ml), ethyl acetate (5 ml) and sodium
hydroxide solution (0.25 M, 1.5 ml), the reaction mixture was
vortexed and allowed to stand to separate the organic layers.
The absorbance in the organic layers was determined (within
2 min of NaOH addition) at 545 nm. The experiments were car-
ried out in triplicates. The results were expressed in absorbance
value (mean ± S.E.M., n= 3 in all the cases) Table 1.
2.7. Determination of experimental partition coefﬁcient
Partition coefﬁcient was determined in between n-octanol and
distilled water using the reported procedure (Fujita et al.,
1964).Table 1 Determination of chemical alkylating activity
expressed in absorbance.
Descriptor Concentration of compounds (lM/ml)
0.5 lM/ml 1.0 lM/ml
CDS-mustard 0.51 ± 0.05 0.74 ± 0.03
N-di(2-chloroethyl)amine 0.49 ± 0.07 0.71 ± 0.04
Blank 0.07 ± 0.02 0.08 ± 0.022.8. Calculation of MlogP
M logP was calculated by the method of Moriguchi et al.
(1992) by the formula:
M logP= 1.464(CX)0.61.221(NO)0.9 · 0.653(PRX)
0.300(UB)0.8
+ 0.335(POL) + 0.726(ALK)0.269(RNG)1.358)
CX = summation of carbon and halogen atoms
NO= total number of nitrogen and oxygen atoms
PRX= proximity effect
UB = total number of unsaturated bonds
POL= number of polar substituents
ALK= alkane, alkene, cycloalkene, cycloalkane dummy
variable
RNG= ring structures
2.9. Calculation of LogBB
LogBB was calculated by the method of (Clark, 1999) by the
formula:
LogBB = 0.0145 PSA+ 0.172 M logP+ 0.131
(PSA = polar surface area)
(M logP=Moriguchi partition coefﬁcient)
2.10. In vitro chemical oxidation studies
By silver nitrate: One milliliter solution of 5% dihydropyridine
derivatives was prepared in methanol. Then 5.0 ml of saturated
methanolic solution of silver nitrate was added to the above
solution. The mixture was shaken and left for 2 min, centri-
fuged and the absorbance of the solution was determined after
making 1.0 ml of solution diluted to 100 ml of methanol and
concentration determined by standard curve. The same proce-
dure was repeated for 4, 6, 8 and 10 min (D.F. 100).
2.11. Kinetics of oxidation of the dihydro derivative (4) (CDS-
mustard) Table 2
Calibration curves: A UV study of compound (4) revealed that
they obey Beer’s Law with a good correlation coefﬁcient and at
a wide range of dilutions from 10 to 60 lg/ml in both methanol
and 2% aqueous methanol. The study was done at 320 nm got
the dihydro derivative (CDS-mustard).
Phosphate buffer: In each of ﬁve tubes containing 0.2 ml of a
10 · 104 M methanolic solution of the freshly prepared dihy-
dro derivative (CDS-mustard) was added 2 ml of freshly pre-
pared phosphate buffer and the tubes were kept at 37 C in a
water bath, at the end of the time period to be investigated,
8 ml of acetonitrile was added, and the tubes were then shaken
vigorously and centrifuged, the absorption of the supernatant
solution at 320 nm was measured against reference.
100% Whole human blood: Blood was withdrawn from a
volunteer shortly before beginning each experiment. The blood
was placed in heparinized tubes and stored on ice until needed,
at which time it was incubated at 37 C. In each of ﬁve tubes
containing 0.2 ml of a 10 · 104 M methanolic solution of
384 R.K. Singh et al.the freshly prepared dihydro derivative (4) was added 2 ml of
fresh heparinized whole human blood and the tubes were kept
at 37 C in a water bath, at the end of the time period to be
investigated, 8 ml of acetonitrile was added, and the tubes were
then shaken vigorously and centrifuged, the absorption of the
supernatant solution at 320 nm was measured. A reference
sample was made by addition of 0.2 ml of methyl alcohol in-
stead of the sample solution following the same procedure.
100% Whole rat blood: Blood was withdrawn from rats
shortly before beginning each experiment. The blood was
placed in heparinized tubes and stored on ice until needed, at
which time it was incubated at 37 C. In each of ﬁve tubes con-
taining 0.2 ml of a 10 · 104 M methanolic solution of the
freshly prepared dihydro derivative (4) was added 2 ml of fresh
rat blood and the tubes were kept at 37 C in a water bath, at
the end of the time period to be investigated, 8 ml of acetoni-
trile was added, and the tubes were then shaken vigorously and
centrifuged, the absorption of the supernatant solution at
350 nm was measured. A reference sample was made by the
addition of 0.2 ml of methyl alcohol instead of the sample solu-
tion following the same procedure.
In 20% human plasma: A freshly prepared solution of the
dihydro derivative (4) (0.2 mL, 6.25 · 104 M) in methanol
was diluted to 10 ml, with 20% plasma (diluted with phos-
phate buffer, pH 7.4). The solution was kept at 30 C and
the UV spectrum was scanned from 400 to 220 nm every
5 min for 30 min against a reference sample made by dilution
of 0.2 mL of methanol with 20% plasma to 10 mL.
In brain homogenate: Rat brain tissue (2.0 gm) was homog-
enized in 10 mL of phosphate buffer, pH 7.4. The homogenate
was centrifuged for 15 min at 3000 rpm, decanted, heated in a
water bath at 50 C for 5 min, and then centrifuged again. The
supernatant solution was diluted to 100 ml with a phosphate
buffer, pH 7.4. To 10 mL of the freshly prepared homogenate
was added 0.2 ml of a 6.25 · 104 M methanolic solution of
the freshly prepared dihydro derivative. The mixture was
scanned at 37 C from 400 to 220 nm every 5 min on a double
beam UV spectrophotometer.
References sample: Methyl alcohol (0.2 ml) was diluted to
10 ml with the brain homogenate solution, and the mixture
was used to record the base line on a UV spectrophotometer
and as a reference of the dihydro derivative (4) sample solution.
Liver homogenate: Rat liver tissue (5.0 gm) was homoge-
nized in 50 mL of phosphate buffer, pH 7.4. The homogenate
was centrifuged for 15 min at 3000 rpm, decanted, heated in a
water bath at 50 C for 5 min, and then centrifuged again. The
supernatant solution was diluted to 250 ml with phosphate
buffer, pH 7.4. To 10 mL of the freshly prepared homogenate
was added 0.2 ml of 6.25 · 104 M methanolic solution of the
freshly prepared dihydro derivative. The mixture was scanned
at 37 C from 400 to 220 nm every 5 min on a double beam UV
spectrophotometer.
Reference sample: Methyl alcohol (0.2 ml) was diluted to
10 ml with the liver homogenate solution, and the mixture was
used to record the base line on a UV spectrophotometer and
as a reference of the dihydro derivative (4) sample solution.
2.12. Stability studies on storage
The CDS-mustard was tested for stability at different storage
conditions by the published method (Al-Obaid et al., 2006).Samples from the prepared CDS-mustard was dried and stored
in dark brown bottles and stored under nitrogen and dry con-
ditions at room temperature (25 C) and in the refrigerator. At
one month interval, each sample was analyzed for its content
of the 1,4-dihydropyridine derivative using UV spectral
analyses.
3. Result and discussion
3.1. Chemical characterization
The major steps for the synthesis of the CDS-mustard agent
are presented in Scheme 1. Initially, the carboxyl group of nic-
otinic acid is activated utilizing thionyl chloride (SOCl2), which
forms the more reactive acyl halide (1). This acyl halide was
reacted with diethanolamine to obtain intermediate, N?-bis
(2-hydroxyethyl)amino)nicotinamide which without further
puriﬁcation was chlorinated by thionyl chloride to obtained
amide (2). The IR spectra of this ﬁnal compound exhibited
the disappearance of –COOH peak at 2400–3300 cm1 and
appearance of sharp absorption at 1661 and 1220–1020 cm1
conﬁrming the presence of the amide group and –C–N func-
tionality. The 1H NMR spectra of these compounds, using
CDCl3 as a solvent show the ethylene bridge yielding two trip-
lets integrating for four protons each. One triplet appeared at d
3.20 ppm which was assigned to –CH2 group adjacent to nitro-
gen. The other triplet at d 3.75 ppm was assigned to the –CH2–
group adjacent to the –Cl group which is more deshielded due
to the electronegativity effect of Chlorine. In addition, other
signals were observed at d 7.4 (t, 1H, J= 2.3 Hz, C5 pyridine
proton), d 8.3 (d, 1H, J= 2.0 Hz, C4 pyridine proton), d 8.7
(d, 1H, J= 1.70 Hz, C6 pyridine proton), and d 9.2 (s, 1H,
C2 pyridine proton).
In another route, nicotinoyl chloride was directly reacted
with neutral base of bis(2-chloroethylamine) to obtain the title
compound in 25% yield. The m.p., IR and NMR spectra were
same for both the compounds. The amide formed was very
hygroscopic. It was sensitive to trace amounts of water and
readily rearranged to 2-(2-chloroethylaminoethyl)esters (5).
These observations are in better accord with an amide-ester
rearrangement reaction (Pettit et al., 1963).
The compound (2) was then quaternized using methyl io-
dide in acetone to give the quaternary salts 1-methyl-3-[bis(2-
chloroethyl)amino]carbamoyl-1,4-dihydro-pyridinium iodide
(3). The structure was conﬁrmed by appearance of 3H singlet
of –NCH3 group at position 1. The obtained quaternary salt
was then subjected to reduction process using sodium dithio-
nite in alkaline medium, to give the corresponding ﬁnal target
compound (4).
3.2. In vitro chemical, biological oxidation and storage studies
The prepared 1,4-dihydropyridines CDS-mustard (4) was sub-
jected to various chemical and biological investigations to eval-
uate the ability of these compounds to cross the BBB and to be
oxidized biologically into their corresponding quaternary
compounds. In this study UV spectrophotometer was used
to detect and monitor the oxidation of the tested 1,4-dihydro-
pyridines into their corresponding quaternary salt either
chemically or in biological ﬂuids. All the kinetic studies were
carried out in triplicate. The K values from the plot were
Figure 2 Log concentration against time of 1-methyl-3-[bis(2-
chloroethyl)amino]carbamoyl-1,4-dihydropyridine (4) CDS-mus-
tard in human plasma, whole human blood and whole rat blood.
Figure 3 Concentration (lg/ml) against time of 1-methyl-3-[bis(2-
chloroethyl)amino]carbamoyl-1,4-dihydropyridine CDS-mustard
(4) in Phosphate Buffer, Brain homogenate and Liver Homogenate.
Figure 4 Log concentration against time of 1-methyl-3-[bis(2-
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mined. Figs. 1–4 show the results of such an investigation.
Pseudo-ﬁrst-order rate constants for the disappearance of
compounds in biological media were determined by linear
regression analysis from a plot of log CDS-mustard versus
time. Quaternary salt which was thought to be converted by
CDS-mustard, did not interfere with the absorption of CDS-
mustard because its kmax was found 275 nm, which was consid-
erably different from that of CDS-mustard (320 nm).
Table 2 shows the calculated half-lives for CDS-mustard in
different media. The in vitro oxidation studies with AgNO3
indicated the facile oxidative conversion of the N-methyl-1,
4-dihydropyridine analog (4) into the corresponding quater-
nary salt (3) with high oxidation rate (K= .0023 ± 0.05, t1/
2 = 3.0 min). The CDS-mustard was quite stable in phosphate
buffer pH 7.4 with K value of .0142 ± 0.8 and t1/2 of 48.8 min.
Liver homogenate was the least stable medium for CDS-mus-
tard with K value of 0.0797 ± 3.6 and t1/2 of 8.7 min. The sta-
bility of CDS-mustard in human plasma was the highest
among all tested biological materials (over 25 min). The CDS
mustard was readily oxidized (t1/2 8.7 min) in rat liver
homogenate.
A parallel study of the storage stability of CDS-mustard at
room temperature and refrigerator (4 C) over a period of
30 days was conducted (Table 3). The acetonitrile solutions
of these compounds were UV checked after the speciﬁed time
period. The CDS-mustard was not much stable at both room
temperature (over 50% decomposed) and in refrigerator (over
10% decomposed) (See Table 3).
The results of these in vitro stability tests were used to com-
pare and evaluate the chemical delivery system to determine
whether the ﬁnal compound met the requirement of the ideal
delivery system. These studies show, then, that brain targeting
is possible but fair stability is required for this compound.
3.3. Alkylating activity assessment
The Q-CDS-mustard was evaluated by its alkylating activity
using 4-(4-nitro-benzyl) pyridine (NBP) as an analytical re-
agent by the method of Pen et al., using spectrophotometric
quantitation. The 4-(4-nitro-benzyl) pyridine reacts with alkyl-
ating agents and gives a purple color upon basiﬁcation (Fig. 5).
The intensity of the produced color is directly proportional to
the degree of alkylation. It is hypothesized that there is aFigure 1 Concentration (lg/ml) against time of 1-methyl-3-[bis(2-
chloroethyl)amino]carbamoyl-1,4-dihydropyridine (4) CDS-mustard
in Human Plasma, Whole Human Blood and Whole Rat Blood.
chloroethyl)amino]carbamoyl-1,4-dihydropyridine (4) CDS-mus-
tard in phosphate buffer, brain homogenate and liver homogenate.
Table 2 Rates of oxidative conversion in biological ﬂuids of
CDS-mustard (4) to the corresponding quaternary pyridinium
salts (3).
Medium Rate constant
K · 102 min1 ± S.E.
t1/2 min ± S.E.
Silver nitrate 0.231 ± 0.05 3.0
Phosphate buﬀer 1.42 ± 0.8 48.8
Human plasma 2.46 ± 1.2 28.1
Whole human blood 4.47 ± 1.6 15.5
Whole rat blood 9.6 ± 2.4 7.22
Brain homogenate 5.46 ± 2.7 12.7
Liver homogenate 7.97 ± 3.6 8.7
S.E. is ±10% of the presented values.
Table 4 Physicochemical parameters of CDS-mustard agent.
Descriptor CDS-mustard agent
Polar surface areaa 23.54 A2




BB3 = Cbrain/Cblood 1.16
Molecular weighta 263.17
No of violationa of rule of 5 0
–NH and –OHa 0
nON valuesa 3
a Calculated by method of Molinspiration.
b Calculated by correlation of PSA to experimental intestinal
absorption.
c M logP was calculated by the method of Moriguchi et al. (1992).
d LogBB, where BB = Cbrain/Cblood, LogBB = LogBB =
0.0145 PSA+ 0.172 M logP+ 0.131.
Table 3 Stability of CDS-mustard (4) upon storage.
Conditions CDS-mustard
Zero days 30 Days % Decomposed
Room temperature (25 C) 0.948 0.426 55.0
Refrigerator (4 C) 0.948 0.816 13.9
386 R.K. Singh et al.correlation between the chemical alkylating activity and anti-
tumor activity. The Q-CDS-mustard proved to be an active
alkylating activity comparable to that of N-di(2-chloro-
ethyl)amine as standard alkylating compound.
3.4. CNS active physicochemical parameters assessment
Since the target compound is designed to be CNS active, the
parameters which affect the blood–brain barrier were selected.
Physicochemical descriptors presented in Table 4 support the
clinical potential of this CDS-mustard agent. Lipophilicity is
one of the most important factors in controlling the interaction
of drugs with biological system (Liu et al., in press).The logP
value of CDS-mustard is determined experimentally and com-
pared with other partition coefﬁcient M logP. Both methods
show a signiﬁcant increased lipophilicity for the CDS-mustard
agent. The polar surface area (PSA) of a drug has been shown
to be an effective means to predict drug transport (Ertl et al.,
2000; Palm et al., 1996, 1997) and its numerical value is inver-
sely correlated with BBB penetration (Kelder et al., 1999). The
most active CNS drug will have PSA of less than 70 A2. PSA
of our CDS-mustard compound is 23.54 A2, which predicts
that greater than 90% of this agent will be absorbed by the
intestine.
Partitioning of drugs between the blood and the CNS can
be expressed in concentration terms Cbrain/Cblood (or BB),
which can be utilized as LogBB similar to LogP. The param-
eter BB or Cbrain/Cblood is profoundly increased for the CDS-
mustard construct 1.16.
A pharmacological parameter referred to as ‘‘Rule of 5’’
accurately predicts drug bioavailability and bioactivity (Lipin-
ski et al., 1997). Highest drug bioavailability and bioactivity
are achieved when there are no violations of the rules.
According to the rule of ﬁve, compounds with number of
violations not more than 1 show good bioavailability and bio-
activity. Analysis of molecular structure by MolinspirationFigure 5 NBP reacts speciﬁcally with quaternary salt of CDS-mu
hydroxide (see broken oval) giving purple color and has a strong absoshowed that CDS-mustard has zero violations of the rule of
ﬁve (Table 4). The target compound CDS-mustard has no
NH or OH hydrogen bond donors which show increased sol-
ubility in cellular membranes. The target compound has
nON value of three which is <10 and has molecular weight
of 263 which is <500 preferable for a compound to be CNS
active. All this properties could permit a better penetration
of the drug through the blood–brain barrier.
4. Conclusion
Redox derivative of bis (2-chloroethyl)amine as alkylating
anticancer moiety was designed in the hope to obtain CNS ac-
tive antitumor agent. Structures of all the synthesized com-
pounds were conﬁrmed by UV, IR, and 1H NMR
techniques. The in vitro chemical alkylation activity studies
(NBP) of Q-CDS-mustard was comparable to that of N,N-
bis(2-chloroethyl)amine moiety as standard alkylating agent.
The in vitro chemical and biological oxidation studies showed
that CDS-mustard could be oxidized into their corresponding
quaternary compounds (3). The obtained values indicate a rea-
sonable stability of the CDS-mustard. The study of some other
physicochemical parameters calculated by online software such
as lipophilicity, LogBB, polar surface area, rule of ﬁve,stard to produce chromophore upon basiﬁcation with sodium
rbance peak at 541 nm.
Synthesis, physicochemical and kinetic studies of redox derivative of bis(2-chloroethylamine) as alkylating 387number of NH or OH hydrogen bond donors, and nON value
also indicates that CDS-mustard can be a potential CNS anti-
tumor agent. But the drawback of this in vitro study is of
course, that CDS-mustard is not so stable in biological media
and it lacks stability when stored at room temperature. Still,
we expect that the results in this work provide a necessary
knowledgebase for future design of novel CDS-mustard by
incorporating various electronegative substituents on the ring
nitrogen of the 1,4-dihydropyridine moiety to enhance the sta-
bility of the prodrug.Acknowledgment
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